EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model

Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada

Cancer Immunology, Immunotherapy · 19.12.2025 · 75 (1)

DOI: 10.1007/s00262-025-04232-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.12.2025. Verfasst von Masato Saito und 6 weiteren Autor:innen. Beteiligte Einrichtung: R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Immunity, Innate, Adaptive Immunity, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indoleamine-Pyrrole 2,3,-DioxygenaseImmunity, InnateAdaptive ImmunityB7-H1 AntigenImmune Checkpoint InhibitorsMelanoma, ExperimentalMelanomaAnimalsMiceMice, Inbred C57BLDisease Models, AnimalTumor MicroenvironmentFemaleCell Line, Tumor

Stichwörter der Autor:innen

Gene signature scoringIDO1 inhibitionImmuno-oncologyImmunotherapyPD-L1 blockadeTumor microenvironment

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenaseB7-H1 AntigenCd274 protein, mouseImmune Checkpoint InhibitorsIDO1 protein, mouse

Autor:innen und Institutionen

  • R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
  • School of Life Science and Technology, Institute of Science Tokyo, Tokyo, Japan. takuji@bio.titech.ac.jp.
  • Metagen, Inc., Yamagata, Japan. takuji@bio.titech.ac.jp.
  • Metagen Therapeutics, Inc., Yamagata, Japan. takuji@bio.titech.ac.jp.
  • Digzyme, Inc., Tokyo, Japan. takuji@bio.titech.ac.jp.

Zitieren

APA

Saito, M., Kunieda, K., Ishii, T., Koshiba, S., Ohashi, R., Kanda, Y., & Yamada, T. (2025). A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model. Cancer Immunology, Immunotherapy, 75(1). https://doi.org/10.1007/s00262-025-04232-8

Vancouver

Saito M, Kunieda K, Ishii T, Koshiba S, Ohashi R, Kanda Y, et al. A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model. Cancer Immunology, Immunotherapy. 2025;75(1). doi:10.1007/s00262-025-04232-8

BibTeX
@article{Saito2025,
  author = {Saito, Masato and Kunieda, Kana and Ishii, Toshihiko and Koshiba, Shoko and Ohashi, Rui and Kanda, Yutaka and Yamada, Takuji},
  title = {A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {75},
  number = {1},
  doi = {10.1007/s00262-025-04232-8}
}
Kostenlos starten →